CN105130884B - 5-methyl-2 (1H) pyridone derivatives and their preparation methods and uses - Google Patents

Abstract

The invention discloses (1H) Pyridione derivatives of 5 methyl 2 or its crystal formation, pharmaceutically acceptable salt, hydrate, solvate or pro-drug shown in formula I；Wherein, R₁Selected from hydrogen, halogen, C₁~C₆Alkyl, C₁~C₆Alkoxy, C₂~C₆Amide groups, C₂~C₆Aminoacyl or C₃~C₆Heterocyclic radical.The invention provides a kind of 5 new methyl 2 (1H) Pyridione derivatives, obvious inhibitory action is respectively provided with to fibroblast proliferation and fibroblasts to secrete fibronectin (Fn), can be used for preparing the medicines such as treatment or prevention fibrotic disease, tumour；The preparation method of compound shown in formula I, has the advantages that process is few, step is easy, reaction condition is gentle, energy consumption is low, efficiency high, cost are low, environmental protection, are especially suitable for the application in industry.

Description

5-Methyl-2(1H)pyridone derivatives and their preparation methods and uses

technical field

The invention relates to a 5-methyl-2(1H) pyridone derivative and its preparation method and application.

Background technique

5-Methyl-2(1H)pyridone, alias: 5-methylpyridin-2-ol, 2-hydroxy-5-methylpyridine, CAS number: 1003-68-5, its chemical structure is shown in Formula A It is mainly used in fields such as organic synthesis.

U.S. Patent No. 3,839,346A discloses pyridone compounds shown in formula B, which have anti-inflammatory, antipyretic, lower serum uric acid levels, and analgesic effects; wherein, the number of substituents R is 0 or 1, and R represents nitro, chlorine, etc. atom, alkyl, methoxy; when R is 0, the compound shown in formula B is 1-phenyl-5-methyl-2-(1H)pyridone (ie pirfenidone). US Patent No. 4,052,509A also discloses pirfenidone, which has good anti-inflammatory and analgesic effects.

Chinese patent CN 1386737 A discloses an anti-fibrosis pyridone drug represented by formula C, which is a 1-multi-substituted phenyl-5-methyl-2-(1H) pyridone compound; wherein, n is 1 or 2. R is F, Cl, Br, I, saturated linear hydrocarbon group, oxo saturated linear hydrocarbon group or halogenated saturated linear hydrocarbon group.

Chinese patent CN 102786467 A discloses an N-substituted aryl pyridone compound shown in formula D, which uses pirfenidone as the lead compound, retains the pyridone core, and is on the 4th position of the N-substituted aryl group Introduce different amine methylene ether structures to obtain N-(4-amine methylene ether) aryl pyridone; wherein, X ₃ is Y(CH ₂ ) _n R ₄ , Y is O or S, and n is 1 -10; said R ₄ is an open-chain or cyclic tertiary amine structure NR ₅ R ₆ , R ₅ and R ₆ are independently selected from straight-chain or branched alkanes containing 1-3 carbon atoms, or R ₅ , R ₆ and N in R ₄ form a five-membered, six-membered or seven-membered ring, and the five-membered, six-membered or seven-membered ring is oxazole, pyrrole, imidazole, pyrazole, piperidine, piperazine, methyl basepiperazine, morpholine or homopiperidine.

Chinese patent CN 101842355 A discloses substituted N-arylpyridones represented by formula E; wherein, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ , R ₉ , R ₁₀ and R ₁₁ are independently selected from the group consisting of hydrogen and deuterium; at least one of R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ , R ₉ , R ₁₀ and R ₁₁ is deuterium; and if R ₇ , R ₈ , R ₉ , R ₁₀ , and R ₁₁ are deuterium, then at least one of R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ is deuterium.

At present, there are no reports of 5-methyl-2 (1H) pyridone derivatives shown in formula I of the present invention; there is no preparation of 5-methyl-2 (1H) pyridone derivatives shown in formula I Methods and uses are reported.

Contents of the invention

The object of the present invention is to provide a new 5-methyl-2 (1H) pyridone derivative.

The 5-methyl-2(1H)pyridone derivative represented by formula I provided by the present invention or its crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug:

Wherein, R ₁ is selected from hydrogen, halogen, C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy group, C ₂ -C ₆ amido group, C ₂ -C ₆ aminoacyl group or C ₃ -C 6 C ₆ heterocyclic group.

Further, R _is selected from hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy or butoxy.

Further, the 5-methyl-2(1H)pyridone derivative shown in formula I is:

Another object of the present invention is to provide a preparation method of the 5-methyl-2(1H)pyridone derivative represented by the above formula I.

A kind of preparation method of 5-methyl-2 (1H) pyridone derivative provided by the present invention, the synthetic route of described preparation method is:

Wherein, R ₁ is selected from hydrogen, halogen, C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy group, C ₂ -C ₆ amido group, C ₂ -C ₆ aminoacyl group or C ₃ -C 6 C heterocyclic group _;

The preparation method comprises the following steps:

a. Take compound 1, alcohol solvent, inorganic alkali aqueous solution, and compound 2, mix them uniformly, react at room temperature, and monitor the completion of the reaction by thin-layer chromatography to obtain a reaction solution;

The mass volume ratio of compound 1 to alcohol solvent is 0.02～0.04:1g/ml; the mass volume ratio of compound 1 to inorganic alkali aqueous solution is 0.15～0.20:1g/ml; the molar ratio of compound 1 to compound 2 is 1:2.1～ 2.5;

The alcohol solvent is selected from any one or both of ethanol and methanol; the inorganic base is selected from any one or both of sodium hydroxide and potassium hydroxide;

The mass fraction of the aqueous inorganic alkali solution is 10% to 30%;

b. Separating and purifying the reaction solution obtained in step a to obtain the compound represented by formula I.

Further, in step a, the synthetic route of compound 1 is:

Compound 1 was prepared according to the following steps:

1. Get 5-methyl-2 (1H) pyridone, inorganic base, p-bromobenzaldehyde and catalyst, carry out reflux reaction in an organic solvent, and monitor the completion of the reaction by thin-layer chromatography to obtain a reaction solution;

The weight ratio of 5-methyl-2(1H)pyridone to inorganic base is 0.1:0.14～0.20; the weight ratio of 5-methyl-2(1H)pyridone to p-bromobenzaldehyde is 0.1:0.17～0.20; The weight ratio of 5-methyl-2(1H)pyridone to catalyst is 0.1:0.02～0.05; the mass volume ratio of 5-methyl-2(1H)pyridone to organic solvent is 0.02～0.05g/ml;

The inorganic base is selected from any one or more than two of potassium carbonate, sodium carbonate, cesium carbonate, potassium hydroxide and sodium hydroxide;

The catalyst is selected from any one or both of cuprous iodide and copper;

The organic solvent is selected from any one or two or more of N,N-dimethylformamide, tetrahydrofuran, and pyridine;

②. Separating and purifying the reaction solution obtained in step ① to obtain compound 1.

Further, in step 1., the synthetic route of 5-methyl-2 (1H) pyridone is:

5-methyl-2 (1H) pyridone is prepared according to the following steps:

i. Take 2-amino-5-picoline and sulfuric acid aqueous solution, mix well, add sodium nitrite aqueous solution to react, after the thin-layer chromatography monitors the reaction, add water, reflux and stir for 15min to 30min to obtain the reaction solution;

The mass volume ratio of 2-amino-5-picoline to sulfuric acid aqueous solution is 1:3.2～3.6g/ml; the mass volume ratio of 2-amino-5-picoline to sodium nitrite aqueous solution is 1:3.0～1 : 3.5g/ml; the mass volume ratio of 2-amino-5-picoline to water is 1:7.5～1:8.0g/ml;

Sulfuric acid aqueous solution is mixed with equal volumes of water and concentrated sulfuric acid; the concentration of sodium nitrite aqueous solution is 0.55-0.65g/ml;

ii. Separating and purifying the reaction solution obtained in step i to obtain 5-methyl-2(1H)pyridone.

Further, in step ii, the method for separating and purifying the reaction solution obtained in step i is: after the reaction solution is cooled, add an inorganic base to adjust the pH to about 7, filter to obtain a filtrate, remove the solvent in the filtrate to obtain a crude product, and weigh Crystallization to obtain 5-methyl-2 (1H) pyridone;

The inorganic base is selected from any one or more than two of sodium carbonate, potassium carbonate, potassium hydroxide and sodium hydroxide.

Further, in step ②, the method for separating and purifying the reaction solution obtained in step ① is: filter the reaction solution to obtain a filtrate; extract the filtrate with ethyl acetate, concentrate the organic phase through the column, and the eluent is petroleum ether: Ethyl acetate=3:1, the solvent was removed and dried to obtain compound 1.

Further, in step a, the compound 2 is:

Further, in step b, the method for separating and purifying the reaction solution obtained in step a is as follows: adjust the pH of the reaction solution to about 7, extract with ethyl acetate, add the organic phase to silica gel to concentrate, pass through the column, and the eluent is petroleum Ether: ethyl acetate = 3:1, the solvent was removed and dried to obtain the compound represented by formula I.

The present invention also provides the above-mentioned 5-methyl-2(1H)pyridone derivative shown in formula I or its crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug. And/or the purposes in the medicine that prevents fibrosis disease, tumor.

The 5-methyl-2(1H)pyridone derivative shown in the above formula I or its crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug is used in the preparation of treatment and/or prevention of fibrosis Use in medicine for diseases or tumor diseases.

Further, the fibrotic diseases include idiopathic pulmonary fibrosis, pulmonary fibrosis, interstitial lung disease, nonspecific interstitial pneumonia, common interstitial pneumonia, endomyocardial fibrosis, mediastinal fibrosis , myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, renal systemic fibrosis, Crohn's disease, old myocardial infarction, scleroderma/systemic sclerosis, neurofibroma, Hermansky-Pudlak syndrome, diabetic nephropathy, renal fibrosis, hypertrophic cardiomyopathy, hypertension-related nephropathy, focal segmental glomerulosclerosis, radiation-induced fibrosis, uterine leiomyoma, alcoholic liver disease, hepatic fat Degeneration, hepatic fibrosis, cirrhosis, hepatitis C virus infection, chronic organ transplant rejection, skin fibrotic disorders, keloids, palmar fascial contracture, Ehlers-Danlos syndrome, dystrophic epidermosol bullosa Any one or more of fibrosis, oral submucosal fibrosis, or fibroproliferative disorders.

For the meanings of the above fibrotic diseases, refer to Chinese patent CN 104093408 A, or give the meanings that those skilled in the art can give according to the disclosed content and context.

The present invention also provides a pharmaceutical composition, which is the 5-methyl-2(1H)pyridone derivative shown in the above formula I or its crystal form, pharmaceutically acceptable salt, Hydrates, solvates or prodrugs are preparations prepared by adding pharmaceutically acceptable adjuvants or auxiliary ingredients as the active ingredient.

The invention provides a new 5-methyl-2(1H)pyridone derivative, which has obvious inhibitory effect on the proliferation of fibroblasts and the secretion of fibronectin (Fn) from fibroblasts, and can be used for the preparation of therapeutic Or prevent fibrotic diseases, tumors and other drugs; the preparation method of the compound shown in formula I of the present invention has the advantages of less steps, simple steps, mild reaction conditions, low energy consumption, high efficiency, low cost, and environmental protection, and is very suitable for industrial on the application.

The compounds and derivatives provided in the present invention may be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, Columbus, OH) nomenclature system.

Definition of terms used in the present invention: Unless otherwise stated, the initial definition provided by a group or term herein applies to the group or term throughout the specification; for terms that are not specifically defined herein, they should be based on the disclosure and context , giving the meanings a person skilled in the art can assign to them.

"Substitution" means that a hydrogen atom in a molecule is replaced by a different atom or molecule.

The minimum and maximum carbon atom content in a hydrocarbon group is indicated by a prefix, for example, the prefix (C a-b) alkyl indicates any alkyl group containing "a" to "b" carbon atoms. Thus, for example, C ₁ -C ₄ alkyl refers to an alkyl group comprising 1 to 4 carbon atoms.

The term "pharmaceutically acceptable" means that a certain carrier, carrier, diluent, excipient, and/or formed salt are generally chemically or physically compatible with other ingredients that constitute a pharmaceutical dosage form, and are physiologically compatible Compatible with receptors.

The terms "salt" and "pharmaceutically acceptable salt" refer to the above-mentioned compounds or their stereoisomers, acidic and/or basic salts formed with inorganic and/or organic acids and bases, and also include zwitterionic salts (internal salts), also include quaternary ammonium salts, such as alkyl ammonium salts. These salts may be obtained directly in the final isolation and purification of the compounds. It can also be obtained by mixing the above-mentioned compound, or its stereoisomer, with a certain amount of acid or base as appropriate (for example, equivalent). These salts may form precipitates in solution and be collected by filtration, or may be recovered after evaporation of the solvent, or may be obtained by freeze-drying after reaction in an aqueous medium. Said salt in the present invention can be hydrochloride, sulfate, citrate, benzene sulfonate, hydrobromide, hydrofluoride, phosphate, acetate, propionate, dibutyl salt, oxalate, malate, succinate, fumarate, maleate, tartrate, or trifluoroacetate.

In some embodiments of the present invention, the present invention includes isotope-labeled compounds, said isotope-labeled compounds are the same as the compounds listed herein, but wherein one or more atoms are replaced by another atom, the atom's The atomic mass or mass number is different from the atomic mass or mass number commonly found in nature. Isotopes that may be introduced into compounds of formula (I) include hydrogen, carbon, nitrogen, oxygen, sulfur, ie ² H, ³ H, ¹³ C, ¹⁴ C, ¹⁵ N, ¹⁷ O, ¹⁸ O, ³⁵ S. Compounds of formula (I) containing the above-mentioned isotopes and/or other atomic isotopes and their stereoisomers, as well as pharmaceutically acceptable salts of the compounds and stereoisomers are all within the scope of the present invention.

Key intermediates and compounds in the present invention are isolated and purified in a manner commonly used in organic chemistry and examples of such methods include filtration, extraction, drying, spin-drying, and various types of chromatography. Alternatively, the intermediate can be carried on to the next step without purification.

In certain embodiments, one or more compounds of the invention may be used in combination with each other. Alternatively, the compound of the present invention may be used in combination with any other active agents for the preparation of drugs or pharmaceutical compositions for regulating cell functions or treating diseases. If a group of compounds is used, the compounds may be administered to the subject simultaneously, separately or sequentially.

The administration method of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative administration methods include (but are not limited to): oral, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with (a) fillers or extenders, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, For example, glycerol; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow agents, such as paraffin; (f) Absorption accelerators such as quaternary ammonium compounds; (g) wetting agents such as cetyl alcohol and glyceryl monostearate; (h) adsorbents such as kaolin; and (i) lubricants such as talc, hard Calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage form may also contain buffering agents.

Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shell materials, such as enteric coatings and others well known in the art. They may contain opacifying agents and, in such compositions, the release of the active compound or compounds may be in a certain part of the alimentary canal in a delayed manner. Examples of usable embedding components are polymeric substances and waxy substances. The active compounds can also be in microencapsulated form, if desired, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, etc.

Besides such inert diluents, the compositions can also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.

Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols, and suitable mixtures thereof.

Dosage forms for topical administration of a compound of this invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required, if necessary.

The pharmaceutically acceptable adjuvant in the present invention refers to the substances contained in the dosage form except the active ingredient.

The pharmaceutically acceptable auxiliary component of the present invention has certain physiological activity, but the addition of this component will not change the leading position of the above-mentioned pharmaceutical composition in the disease treatment process, but only play an auxiliary effect, and these auxiliary effects are only It is the utilization of the known activity of the ingredient, and it is a commonly used adjuvant therapy in the field of medicine. If the above-mentioned auxiliary components are used in conjunction with the pharmaceutical composition of the present invention, it should still belong to the protection scope of the present invention.

Apparently, according to the above content of the present invention, according to common technical knowledge and conventional means in this field, without departing from the above basic technical idea of the present invention, other various forms of modification, replacement or change can also be made.

The above-mentioned content of the present invention will be further described in detail below through specific implementation in the form of examples. However, this should not be construed as limiting the scope of the above-mentioned subject matter of the present invention to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention.

detailed description

The raw materials and equipment used in the specific embodiment of the present invention are all known products, obtained by purchasing commercially available products.

Example 1

Among them, "rf" is the abbreviation of reflux, and its Chinese meaning is "reflux".

In a 25ml reaction flask, first add 3.4ml of a solution (50%, volume fraction) consisting of 17ml H ₂ O and 17ml of concentrated sulfuric acid, then add 1g (0.01mol) of 2-amino-5-picoline, wash with ice salt The bath was cooled to below 10°C, and after a few minutes of stirring, the reaction solution turned milky white. Then slowly add dropwise a solution consisting of (1.72g NaNO ₂ and 3mLH ₂ O) mixed. During the dropwise addition, an irritating gas will be produced. Finished (about 40min). Then add 8mL H ₂ O, reflux and stir for 15 minutes, cool, add anhydrous Na ₂ CO ₃ under stirring, make the reaction solution neutral (yellow-brown solid is produced), filter, spin the obtained filtrate to dryness, and then wash with absolute ethanol It was dissolved and filtered, and the resulting filtrate was spin-dried again to obtain 0.87 g of a yellow-brown solid (5-methyl-2(1H)pyridone).

Add 0.1g (1mmol) 5-methyl-2 (1H) pyridone, 0.14g K ₂ CO ₃ , 0.17g p-bromobenzaldehyde, 0.05g CuI, 5ml DMF as solvent in the one-mouth bottle, carry out reflux stirring reaction, TCL Monitor until the reaction is complete, stop the reaction, filter, extract the filtrate with EA (ethyl acetate), concentrate the organic layer through the column (PE: EA = 3:1, volume ratio, PE is petroleum ether), and obtain yellowish or white flakes 0.08 g of solid, which is compound 1.

In the reaction flask, add 0.3g of compound 1 and 15ml of absolute ethanol, add 2mL of 10% (mass fraction) NaOH aqueous solution dropwise under magnetic stirring until completely dissolved, cool in an ice bath, add 0.40g of p-methylacetophenone, remove the ice In a water bath, the reaction temperature was raised to room temperature. After the reaction was monitored by TLC, the pH was adjusted to ≈7 with dilute HCl, extracted with ethyl acetate, the organic layer was concentrated by adding 200 mesh silica gel, and passed through the column (petroleum ether: ethyl acetate=3: 1), the obtained product was spin-dried to obtain the compound shown in formula Ia with a yield of 73%.

Compound represented by formula Ia: yellow solid (yellow solid), melting point (mp) is 94-95°C;

¹ H NMR (400MHz, DMSO-d6) δ: 7.96～8.11(m, 1H, CH), 7.83(m, 2H, ArH), 7.21～7.60(m, 10H, ArH), 6.45(d, J=8.0 Hz, 1H, CH), 6.39(d, J=9.6Hz, 1H, CH), 3.97(m, 1H, CH), 3.40(d, J=20Hz, 2H, CH ₂ ), 2.37(s, 6H, CH ₃ ), 2.04 (d, J=21.1Hz, 3H, CH ₃ );

¹³ C NMR (100MHz, DMSO-d6) 197.85, 160.34, 143.50, 136.06, 134.19, 129.19, 128.02, 126.25, 120.10, 114.22, 44.12, 39.53, 21.09, 16.32; IR (KBr, n, ^cm90 ): 3 ,2973,1676,1610,1509,1412,1280,1185,1088,1048,882,820,590;

HRMS (ESI) calcd for C ₃₁ H ₂₉ NO ₃ [M+Na] ⁺ 463.2147 found 486.2051.

Example 2

According to the method described in Example 1, replacing "p-methylacetophenone" with "p-chloroacetophenone", the compound shown in formula Ib was obtained.

Compound represented by formula Ib: yellow solid (yellow solid), melting point (mp) is 66-67°C;

¹ H NMR (400MHz, DMSO-d6) δ: 8.02(d, J=8.8Hz, 4H, ArH), 7.62(d, J=8.4Hz, 4H, ArH), 7.51(d, J=8.4Hz, 2H ,ArH),7.37～7.40(m,2H,CH),7.30(d,J=8.4Hz,2H,ArH),6.43(d,J=10.0Hz,1H,CH),3.97～4.03(m,2H , CH), 3.55 (d, J=6.8Hz, 4H, CH ₂ ), 2.06 (s, 6H, CH ₃ );

¹³ C NMR (100MHz, DMSO-d6) 197.40, 160.34, 143.95, 139.04, 136.02, 135.26, 129.84, 129.76, 126.31, 120.11, 113.91, 44.21, 39.53, 35.53, 16.23; IR ( ^KBr , n, :3429,1673,1590,1400,1262,1091,804,590;

HRMS (ESI) _calcd for _{C29H23Cl2NO3 [} M+Na] ⁺ _503.1055 found 526.0963.

Example 3

According to the method described in Example 1, replacing "p-methylacetophenone" with "p-fluoroacetophenone", the compound represented by formula Ic was obtained.

Compound represented by formula Ic: gray solid (gray solid), melting point (mp) is 60-62°C;

¹ H NMR (400MHz, DMSO-d6) δ: 8.06(dd, J1=6.0Hz, J2=8.4Hz, 4H, ArH), 7.48(d, J=8.4Hz, 2H, CH), 7.26～7.35(m ,8H,ArH),6.40(d,J=10.0Hz,1H,CH),3.97～4.04(m,1H,CH),3.52(d,J=6.8Hz,4H,CH ₂ ),2.02(s, 6H, CH ₃ );

¹³ C NMR(100MHz,DMSO-d6)196.93,166.24,163.74,160.35,144.06,142.81,139.02,136.01,133.37,130.95,128.14,126.30,120.11,115.73,113.91,44.17,39.11,35.87,16.21；IR( KBr,n,cm ^-1 ):2925,1675,1596,1506,1410,1364,1277,1230,1156,990,832,586;

HRMS (ESI) calcd for _C29H23F2NO3 [M ^{+Na] +} _{471.1646 found 494.1549} .

In order to illustrate the beneficial effects of the present invention, the present invention provides following test example:

Experimental Materials and Instruments

1. Main experimental instruments

Biochemical incubator (SANYO);

Microplate reader (biorad);

2. Main experimental materials and reagents

MRC-5 cell line (human embryonic lung fibroblast);

MTT (sigma, Cat. No. M5655);

DMSO, (sigma, Cat. No. 67685);

Fn ELISA Kit: Boster (Cat.No.EK0349);

Test example 1

Detect the effect of the compound on the proliferation of human lung fibroblasts (MTT method: 24-hour continuous action group and 48-hour continuous action group); test the effect of the compound on the secretion of Fn from human lung fibroblasts (ELISA method).

references:

Tao Lijian, Zhang Jun, Hu Gaoyun, Chen Zhuo, Gong Juan. Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H)pyridone on rat kidney fibroblasts. Journal of Central South University (Medical Edition) ), 2004, 29(2): 139-141.

Xianchai Lin, Minbin Yu, Kaili Wu, Hongzhi Yuan, and Hua Zhong. Effects of Pirfenidone on Proliferation, Migration, and Collagen Contraction of Human Tenon's Fibroblasts In Vitro. Investigative Ophthalmology & Visual Science, August 2009, Vol.50, No.8: 3763 ~3770.

Sample handling:

Dissolve pirfenidone and the compound represented by formula I of the present invention in DMSO respectively, filter and sterilize through a 0.22 μm filter membrane to prepare solutions of different concentrations, store at -20°C, and thaw before use.

Cell culture:

MRC-5 cells (human embryonic lung fibroblasts) were inoculated in a culture dish containing 10% fetal bovine serum in DMEM medium (100 U/ml penicillin, 100 U/ml streptomycin), placed in 5% CO ₂ , Cultured in a 37°C incubator. After the cells grew confluent, they were digested and passaged with 0.25% trypsin, and the MRC-5 cells of passage 3-10 were used for the experiment.

1. Inhibition rate detected by MTT method

MTT assay, also known as MTT colorimetric assay, is a method for detecting cell survival and growth.

Adjust the concentration of MRC-5 cells to 8×10 ³ /well with DMEM medium containing 10% fetal bovine serum, inoculate them in 96-well plates, and culture them in a 5% CO ₂ , 37°C incubator for 24 hours. Add different concentrations of The DMSO solution (100 μg/ml, 500 μg/ml, 1000 μg/ml) of the compound shown in formula I of the present invention is positive with the DMSO solution (100 μg/ml, 500 μg/ml, 1000 μg/ml) of pirfenidone of different concentrations For the control group, only the same amount of DMEM culture solution was added to the blank control group, and 5 parallel wells were set up in each group. The culture plate was placed in a 5% CO ₂ , 37°C incubator, and the culture was continued for 24 hours. After 48 hours, 20 μl MTT (5 mg/ ml), and then placed in an incubator for incubation for 4 hours. After discarding the supernatant, add 150 μl DMSO to each well, mix well for 10 minutes, and read the absorbance A value of each well at 570 nm on a microplate reader.

Calculate the cell proliferation inhibition rate according to the absorbance A value, the formula is as follows:

Inhibition rate (%) = (blank control group A value - test group A value) / blank control group A value × 100%

The statistical software SPSS 17.0 was used for statistical analysis, and all quantitative data were expressed as mean ± standard deviation (mean ± s), and the comparison between groups was performed by one-way analysis of variance, with P < 0.05 being considered statistically significant, and P < 0.01 being considered statistically significant. There are significant differences.

The results of the MTT assay are shown in Table 1.

Table 1, the influence of the compounds shown in formula I of the present invention on MRC-5 cells

Compared with blank control group, * means P<0.05, ** means P<0.01; compared with pirfenidone 500 μg/mL, △ means P<0.05, △△ means P<0.01.

The test results show that the compound represented by formula I of the present invention has obvious inhibitory effect on fibroblast proliferation, and the inhibitory rate increases with the increase of dosage.

2. Detection of expression of fibronectin (Fn)

The expression of Fn was determined by ELISA kit.

Adjust the concentration of MRC-5 cells to 8×10 ³ /well with DMEM medium containing 10% fetal bovine serum, inoculate them in 96-well plates, and culture them in a 5% CO ₂ , 37°C incubator for 24 hours. Add different concentrations of The DMSO solution (100 μg/ml, 500 μg/ml, 1000 μg/ml) of the compound shown in formula I of the present invention, the DMSO solution (100 μg/ml, 500 μ g) of pirfenidone (PF refers to pirfenidone) of different concentrations /ml, 1000μg/ml) as the positive control, the blank control group only added the same amount of DMEM culture solution, placed the culture plate in a 5% CO ₂ , 37°C incubator, and continued to culture for 48 hours, then took the cell supernatant and added it to the test Well, operate according to the method provided by the Fn kit. After measuring the absorbance A value with a microplate reader, compare it with the standard curve to obtain the Fn content.

The statistical software SPSS 17.0 was used for statistical analysis, and all quantitative data were expressed as mean ± standard deviation (mean ± s), and the comparison between groups was performed by one-way analysis of variance, with P < 0.05 being considered statistically significant, and P < 0.01 being considered statistically significant. There are significant differences.

The test results of Fn expression are shown in Table 2.

Table 2, the influence of the compound shown in formula I of the present invention on Fn expression

Compared with blank control group, * means P<0.05, ** means P<0.01.

The test results show that the compound represented by the formula I of the present invention can inhibit the secretion of fibronectin (Fn) from fibroblasts, and its inhibitory effect increases with the increase of the dosage.

In summary, the present invention provides a new 5-methyl-2 (1H) pyridone derivative, which has obvious inhibitory effect on fibroblast proliferation and fibroblast secretion of fibronectin (Fn), It can be used to prepare drugs for treating or preventing fibrotic diseases and tumors; the preparation method of the compound represented by formula I of the present invention has the advantages of less steps, simple steps, mild reaction conditions, low energy consumption, high efficiency, low cost, and environmental protection. Advantages, very suitable for industrial applications.

Claims (14)

1. 5-methyl-2(1H)pyridone derivatives shown in formula I or pharmaceutically acceptable salts thereof: Wherein, R ₁ is selected from hydrogen, halogen, C ₁ -C ₆ alkyl or C ₁ -C ₆ alkoxy. 2. According to claim 1 formula I shown 5-methyl-2 ( _1H ) pyridone derivative or its pharmaceutically acceptable salt, it is characterized in that: R is selected from hydrogen, fluorine, chlorine, bromine, iodine, Methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, or butoxy. 3. According to claim 1, 5-methyl-2 (1H) pyridone derivatives shown in formula I or pharmaceutically acceptable salts thereof, characterized in that: 5-methyl-2 (1H) pyridine shown in formula I Ketone derivatives are: 4. A preparation method of 5-methyl-2 (1H) pyridone derivatives, characterized in that: the synthetic route of the preparation method is: Wherein, R ₁ is selected from hydrogen, halogen, C ₁ -C ₆ alkyl or C ₁ -C ₆ alkoxy; The preparation method comprises the following steps: a. Take compound 1, alcohol solvent, inorganic alkali aqueous solution, and compound 2, mix them uniformly, react at room temperature, and monitor the completion of the reaction by thin-layer chromatography to obtain a reaction solution; The mass volume ratio of compound 1 to alcohol solvent is 0.02～0.04:1g/ml; the mass volume ratio of compound 1 to inorganic alkali aqueous solution is 0.15～0.20:1g/ml; the molar ratio of compound 1 to compound 2 is 1:2.1～ 2.5; The alcohol solvent is selected from any one or both of ethanol and methanol; the inorganic base is selected from any one or both of sodium hydroxide and potassium hydroxide; The mass fraction of the aqueous inorganic alkali solution is 10% to 30%; b. Separating and purifying the reaction solution obtained in step a to obtain the compound represented by formula I. 5. The preparation method according to claim 4, characterized in that: in step a, the synthetic route of compound 1 is: Compound 1 was prepared according to the following steps: 1. Get 5-methyl-2 (1H) pyridone, inorganic base, p-bromobenzaldehyde and catalyst, carry out reflux reaction in an organic solvent, and monitor the completion of the reaction by thin-layer chromatography to obtain a reaction solution; The weight ratio of 5-methyl-2 (1H) pyridone and inorganic base is 0.1: 0.14～0.20; the weight ratio of 5-methyl-2 (1H) pyridone and p-bromobenzaldehyde is 0.1: 0.17～0.20; The weight ratio of 5-methyl-2(1H)pyridone to catalyst is 0.1:0.02～0.05; the mass volume ratio of 5-methyl-2(1H)pyridone to organic solvent is 0.02～0.05g/ml; The inorganic base is selected from any one or more than two of potassium carbonate, sodium carbonate, cesium carbonate, potassium hydroxide and sodium hydroxide; The catalyst is selected from any one or both of cuprous iodide and copper; The organic solvent is selected from any one or two or more of N,N-dimethylformamide, tetrahydrofuran, and pyridine; ②. Separating and purifying the reaction solution obtained in step ① to obtain compound 1. 6. the preparation method according to claim 5, is characterized in that: step 1. in, the synthetic route of 5-methyl-2 (1H) pyridone is: 5-methyl-2 (1H) pyridone is prepared according to the following steps: i. Take 2-amino-5-picoline and sulfuric acid aqueous solution, mix well, add sodium nitrite aqueous solution to react, after the thin-layer chromatography monitors the reaction, add water, reflux and stir for 15min to 30min to obtain the reaction solution; The mass volume ratio of 2-amino-5-picoline to sulfuric acid aqueous solution is 1:3.2～3.6g/ml; the mass volume ratio of 2-amino-5-picoline to sodium nitrite aqueous solution is 1:3.0～1 : 3.5g/ml; the mass volume ratio of 2-amino-5-picoline to water is 1:7.5～1:8.0g/ml; Sulfuric acid aqueous solution is mixed with equal volumes of water and concentrated sulfuric acid; the concentration of sodium nitrite aqueous solution is 0.55-0.65g/ml; ii. Separating and purifying the reaction solution obtained in step i to obtain 5-methyl-2(1H)pyridone. 7. The preparation method according to claim 6, characterized in that: in step ii, the method for separating and purifying the reaction solution obtained in step i is: after the reaction solution is cooled, add an inorganic base, adjust the pH to about 7, filter, Obtain filtrate, remove the solvent in the filtrate, obtain crude product, recrystallize, obtain 5-methyl-2 (1H) pyridone; The inorganic base is selected from any one or more than two of sodium carbonate, potassium carbonate, potassium hydroxide and sodium hydroxide. 8. The preparation method according to claim 5, characterized in that: in step 2., the method for separating and purifying the reaction solution obtained in step 1. is: the reaction solution is filtered to obtain the filtrate; the filtrate is extracted with ethyl acetate, and The organic phase was concentrated and passed through the column, the eluent was petroleum ether: ethyl acetate = 3:1, the solvent was removed and dried to obtain compound 1. 9. The preparation method according to claim 4, characterized in that: in step a, the compound 2 is: 10. The preparation method according to claim 4, characterized in that: in step b, the method for separating and purifying the reaction solution obtained in step a is: adjust the pH of the reaction solution to be about 7, extract with ethyl acetate, and extract the organic The phase was added to silica gel to concentrate, passed through the column, the eluent was petroleum ether: ethyl acetate = 3:1, the solvent was removed and dried to obtain the compound represented by formula I. 11. 5-methyl-2 (1H) pyridone derivatives or pharmaceutically acceptable salts thereof shown in formula I according to any one of claims 1 to 3 are used in the preparation of treatment and/or prevention of fibrotic diseases or tumors Use in medicine for disease. 12. The use according to claim 11, characterized in that: said fibrotic diseases include pulmonary fibrosis, interstitial lung disease, non-specific interstitial pneumonia, common interstitial pneumonia, endomyocardial fibrosis fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, renal systemic fibrosis, Crohn's disease, old myocardial infarction, scleroderma/systemic sclerosis, nerve fibers tumor, Hermansky-Pudlak syndrome, diabetic nephropathy, renal fibrosis, hypertrophic cardiomyopathy, hypertension-related nephropathy, focal segmental glomerulosclerosis, radiation-induced fibrosis, uterine leiomyoma, alcoholic Liver disease, hepatic steatosis, hepatic fibrosis, cirrhosis, hepatitis C virus infection, chronic organ transplant rejection, skin fibrotic disorders, keloids, palmar fascial contracture, Ehlers-Danlos syndrome, dystrophic Any one or more of epidermolysis bullosa, oral submucosal fibrosis, or fibroproliferative disorders. 13. The use according to claim 12, characterized in that: said pulmonary fibrosis is idiopathic pulmonary fibrosis. 14. A pharmaceutical composition, characterized in that: the pharmaceutical composition is 5-methyl-2(1H)pyridone derivative or its derivative shown in formula I according to any one of claims 1 to 3 A pharmaceutically acceptable salt is a preparation prepared by adding pharmaceutically acceptable auxiliary materials to the active ingredient.